Astute Medical raised $2 million in a new round of debt financing, according to an SEC filing posted today.
San Diego-based Astute Medical develops and produces the NephroCheck, a device designed to test for acute kidney injury in patients who have suffered a serious cardiac or respiratory event.
Money in the round came from 13 anonymous sources, according to the SEC filing, and the company has not yet stated how it plans to spend funds raised in the round.
The funding round includes a principal amount of convertible notes and purchase price of warrants, according to the SEC filing, with the exercise price of warrants not determinable currently.
Last October, Astute Medical said it raised $20 million from Shanghai Fosun Pharmaceutical (SHA:600196) and inked a distribution deal with the Chinese company for its NephroCheck kidney-injury test.
The multi-year deal calls for Shanghai Fosun’s Long March Medicine Science subsidiary to distribute NephroCheck on the Astute140 meter in China. NephroCheck is marketed in the U.S. by Ortho-Clinical Diagnostics.
Two years ago, Astute won 510(k) clearance for NephroCheck.